CIK 0001628171
- Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472029180
- Phone
- +1 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,328,124
- in 21 filings, $85.3M under 10b5-1 plans
Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-15 | Cislini Jeff General Counsel | Sale 10b5-1 | −2,554 | $55.13 | $141K | 43,080 |
| 2024-11-13 | Kelsey Stephen Michael See Remarks | Option exercise 10b5-1 | +16,666 | $4.09 | $68K | 281,074 |
| 2024-11-13 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −13,778 | $58.49 | $806K | 267,296 |
| 2024-11-13 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −2,888 | $59.45 | $172K | 264,408 |
| 2024-11-13 | Kelsey Stephen Michael See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,666 | 6,666 | ||
| 2024-11-06 | Cislini Jeff General Counsel | Option exercise 10b5-1 | +6,000 | $36.57 | $219K | 51,634 |
| 2024-11-06 | Cislini Jeff General Counsel | Sale 10b5-1 | −6,000 | $60.00 | $360K | 45,634 |
| 2024-11-06 | Cislini Jeff General Counsel | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 30,000 | ||
| 2024-11-04 | GOLDSMITH MARK A See Remarks | Option exercise 10b5-1 | +50,900 | $4.09 | $208K | 351,070 |
| 2024-11-04 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −50,900 | $55.56 | $2.8M | 300,170 |
| 2024-11-04 | GOLDSMITH MARK A See Remarks | Option exercise 10b5-1 | +36,600 | $0.49 | $18K | 336,770 |
| 2024-11-04 | GOLDSMITH MARK A See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −50,900 | 181,229 | ||
| 2024-11-04 | GOLDSMITH MARK A See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −36,600 | 30,846 | ||
| 2024-11-01 | GOLDSMITH MARK A See Remarks | Option exercise 10b5-1 | +9,100 | $4.09 | $37K | 309,270 |
| 2024-11-01 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −9,100 | $55.02 | $501K | 300,170 |
| 2024-11-01 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −5,000 | $55.03 | $275K | 20,424 |
| 2024-11-01 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −5,000 | $55.02 | $275K | 20,424 |
| 2024-11-01 | GOLDSMITH MARK A See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,100 | 232,129 | ||
| 2024-10-31 | Patel Sushil Director | Option exercise 10b5-1 | +5,000 | $24.84 | $124K | 24,948 |
| 2024-10-31 | Patel Sushil Director | Sale 10b5-1 | −5,000 | $54.14 | $271K | 19,948 |
Page 20 of 29 · 569 trades